Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
The short answer for OTP operators
Yes, an OTP can initiate methadone via telehealth, but only via audio-visual telehealth, only when a practitioner determines an adequate evaluation is possible remotely, and only inside the OTP framework at 42 CFR Part 8. Methadone for OUD still cannot be prescribed outside an OTP. That did not change when the DEA and HHS published the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities running January 1 through December 31, 2026.
Two rules govern this space and operators keep conflating them. The SAMHSA 42 CFR Part 8 Final Rule (89 FR 7528) sets what an OTP may do clinically. The DEA/HHS Fourth Temporary Rule sets what a DEA-registered practitioner may prescribe via telemedicine generally. They interact. If your compliance team treats them as one policy, expect a finding on your next survey.
What 42 CFR Part 8 actually says about telehealth for methadone
SAMHSA published the revised Part 8 on February 2, 2024. The effective date was April 2, 2024, and the compliance date was October 2, 2024. If your policies still cite the 2001 framework or the COVID-era exemption letters, you are already behind.
The rule text at 42 CFR 8.12(f)(2) is specific: for schedule II medications such as methadone, audio-visual telehealth platforms must be used, except when not available to the patient. When audio-visual is unavailable, audio-only is acceptable only when the patient is in the presence of a licensed practitioner registered to prescribe (including dispense) controlled medications. The OTP practitioner then reviews the examination results and orders treatment medications as indicated.
SAMHSA’s own patient-facing summary confirms the asymmetry: telehealth, both audio-visual and audio-only, for screening the initiation of buprenorphine, and audio-visual screening for the initiation of methadone under certain conditions.
Why the asymmetry? SAMHSA explains it plainly in the Part 8 FAQ: methadone carries a higher risk of sedation than buprenorphine, so visual assessment lets practitioners identify signs of sedation and protect the patient. Audio-only methadone induction is a narrow exception, not a workflow you build a program around. For buprenorphine, audio-only is far more workable. Operators who lump both drugs into one telehealth SOP will fail a mock survey on this alone.
SAMHSA is direct that methadone stays inside the OTP walls. In the Federal Register response to comments, the agency stated: the final 42 CFR part 8 rule only applies to dispensing of methadone in OTPs. The rule does permit a medication unit inside a pharmacy where state and space allow. That is not the same as a telehealth methadone startup.
The DEA 2026 extension, and why it does not do what most people think it does for methadone
On December 31, 2025, DEA and HHS published the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, effective January 1, 2026 through December 31, 2026. DEA Assistant Administrator Cheri Oz framed it this way in the agency’s press release: “DEA supports telehealth access for patients who need medication, but not at the expense of public safety.”
Here is what the extension actually covers. A DEA-registered practitioner may remotely prescribe Schedule II-V controlled substances via audio-video telemedicine without a prior in-person visit, and audio-only remains available for certain FDA-approved Schedule III-V drugs used for maintenance and withdrawal management of OUD. Buprenorphine (Schedule III) sits squarely inside that audio-only carve-out. Methadone is Schedule II. Audio-only will not carry it. And methadone for OUD is not prescribed at retail; it is dispensed by a certified OTP.
Holland & Knight’s healthcare team read the extension the same way: the temporary rule effectively serves as the broadest and most flexible pathway for telemedicine prescribing during the transition period, while the final rules provide more structured, conditional pathways. Translation: a one-year bridge while DEA tries to finalize a permanent Special Registration for Telemedicine. Operators betting a pro forma on that permanent framework landing in 2026 should build a downside case where it slips again.
What this means operationally for OTPs in Florida, Ohio, Texas, and everywhere else
The federal ceiling is not the state floor. SAMHSA’s Division of Pharmacologic Therapies supports more than 1,900 OTPs treating more than 600,000 patients each year, and every one of them answers to a State Opioid Treatment Authority (SOTA) that can be stricter than Part 8.
The variation is not theoretical. SAMHSA’s 2025 baseline assessment collected responses from 46 SOTAs and 241 OTPs on adoption of 13 key elements of the revised Part 8. Region 10 adopted the most changes on average, with a mean of 13. Region 6 adopted the fewest, with a mean of 7.6. The report used telehealth initiation of methadone as its worked example of how federal and state rules interact, and stated the operator-side risk directly: even though the revised federal regulations allow for this, if state/territory rules do not permit it, the OTP cannot implement this service.
Florida operators I work with have moved faster on take-home flexibility than on telehealth induction, largely because SOTA guidance on audio-visual methadone screening lags the federal rule. Ohio programs have leaned into nurse practitioner and PA ordering, which Part 8 now permits where state law allows. Texas programs are still wrestling with how audio-visual induction interacts with existing state controlled-substance protocols. If your compliance officer has not pulled your SOTA’s written guidance in the last 90 days, you are operating on assumptions.
Three specific things to fix before your next accreditation survey:
- Split your telehealth SOPs by drug and schedule. Methadone induction (audio-visual, with the narrow audio-only exception), buprenorphine induction (audio-only permitted more broadly), and general controlled-substance follow-up prescribing under the DEA extension are three different workflows. One document covering all three will produce findings.
- Document the practitioner’s determination that telehealth evaluation is adequate. Part 8 hinges on that clinical judgment. If it is not in the chart with rationale, the encounter is not defensible.
- Confirm your SOTA has adopted the specific element you are relying on. The Part 8 rule permits audio-visual methadone screening. Your state may not have implemented it. Federal permission does not preempt a stricter state rule.
How AHS reads the near-term risk for OTP operators and PE-backed platforms
The Part 8 rule is genuinely good policy for patients and reasonably workable for operators who take the time to implement it. The DEA extension is a stopgap. Neither is a green light to run methadone induction like a telepsychiatry startup.
One more operator-side reality on the demand side. The DEA cited Brown University electronic-medical-record analysis showing that the September 2025 lapse of Medicare telehealth flexibilities produced a 24 percent reduction in fee-for-service telemedicine visits in the first 17 days of the shutdown, with some states seeing a 40 percent reduction. If your census projections assume the current framework is permanent, model the cliff. December 31, 2026 is thirteen months of runway.
For founders in feasibility on a new OTP: your pro forma should not assume audio-only methadone induction as a growth lever. It should assume audio-visual induction where your SOTA has adopted the change, and it should carry the cost of the in-person infrastructure Part 8 still requires for dispensing, observed dosing, and clinical oversight.
For PE-backed buyers doing diligence on an OTP platform: ask to see the telehealth policies, the practitioner-adequacy documentation in a random chart sample, the SOTA correspondence file, and the DEA registration for every dispensing location. A gap in any one of those can stop a site from dispensing a single dose. That is a covenant risk, not a compliance footnote.
For sitting COOs and executive directors: schedule your mock survey against the current rule, not the version your accreditation body walked you through in 2023. The surveyor focus in 2026 will be documentation of the telehealth adequacy determination and alignment between your written policy and your actual practice. If those two do not match, you already have your finding.
Frequently asked questions
Can an OTP initiate methadone entirely via telehealth under the 2024 Part 8 rule?
Only via audio-visual telehealth, and only when a practitioner determines an adequate evaluation can be accomplished remotely. SAMHSA’s Part 8 FAQ is explicit that the screening exam for methadone should be conducted via an audio-visual platform because methadone carries a higher risk of sedation than buprenorphine. Audio-only methadone screening is permitted only when audio-visual is unavailable to the patient AND the patient is physically present with a licensed practitioner registered to prescribe controlled medications. Methadone for OUD still cannot be prescribed outside the OTP framework.
Does the DEA’s Fourth Temporary Extension through December 31, 2026 let us prescribe methadone via telemedicine?
Not in a way that changes OTP operations. The Federal Register text authorizes DEA-registered practitioners to prescribe Schedule II-V controlled substances via audio-video telemedicine without a prior in-person visit, and audio-only for FDA-approved Schedule III-V OUD medications like buprenorphine. Methadone is Schedule II, and for OUD it is dispensed by a certified OTP under 42 CFR Part 8, not prescribed at retail pharmacy. Your methadone induction workflow is governed by Part 8, not the DEA extension.
If federal Part 8 permits audio-visual methadone screening, does that override my state’s rules?
No. States can be stricter than Part 8, but not more lenient. SAMHSA’s 2025 baseline assessment collected responses from 46 SOTAs and 241 OTPs and used telehealth initiation of methadone as the worked example of federal-state interplay, warning that if state or territory rules do not permit an element, the OTP cannot implement it. Region 10 adopted an average of 13 of the 13 tracked elements, while Region 6 averaged 7.6. Before launching telehealth methadone induction, confirm in writing that your State Opioid Treatment Authority has adopted the specific element you are relying on.
What is the biggest operator-side risk if the DEA telemedicine flexibilities lapse at the end of 2026?
Census disruption on the buprenorphine and general controlled-substance prescribing side, not on core OTP methadone dispensing. When Medicare telehealth flexibilities lapsed on September 30, 2025, the DEA cited Brown University data showing a 24 percent reduction in fee-for-service telemedicine visits in the first 17 days of the shutdown, with some states seeing a 40 percent reduction. Model a downside pro forma that assumes the Special Registration for Telemedicine is not finalized before December 31, 2026, and stress-test your telehealth-dependent revenue lines accordingly.
References
- Federal Register: Medications for the Treatment of Opioid Use Disorder (89 FR 7528, February 2, 2024)
- eCFR: 42 CFR Part 8. Medications for the Treatment of Opioid Use Disorder
- SAMHSA: 42 CFR Part 8 Final Rule Frequently Asked Questions
- SAMHSA: 42 CFR Part 8 Final Rule. Expanding Access and Flexibility for Patients
- Federal Register: Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
- DEA Press Release: DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care (December 31, 2025)
- Holland & Knight: DEA and HHS Extend Telemedicine Prescribing Flexibilities Through 2026
- SAMHSA: Revised Regulations for Opioid Treatment Programs. Establishing a Baseline to Measure Progress Over Time (2025)
- SAMHSA: Opioid Treatment Program Information for Providers
- Fierce Healthcare: DEA Issues Fourth Extension of Telehealth Controlled Substance Flexibilities